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Summary: The importance of the association of antiphos-
pholipid antibodies (aPL Abs) with the features of type II dia-
betes mellitus has not yet been elucidated. The aim of this
work was to investigate the association of aPL Abs with
adiponectin and non-esterified fatty acids (NEFA) in type II
diabetes mellitus patients without micro and/or macrovascu-
lar complications, and to analyze the differences between the
male and female patients with regard to the abovemen-
tioned parameters. Male patients with type II diabetes melli-
tus showed a positive correlation between NEFA concentra-
tions and anti-oxLDL antibodies (r=0.334, p=0.019). A
weak, but statistically significant correlation between adipo -
nectin concentrations and the IgM isotype of anti-annexin A5
antibodies was found in type II diabetes mellitus patients
(r=0.285, p=0.011). The presence of a positive correlation
between NEFA and anti-oxLDL antibodies might be useful in
the detection of patients with premature atherosclerosis in
type II diabetes mellitus patients without any micro and/or
macrovascular complications among type II diabetes mellitus
patients.
Keywords: antiphospholipid antibodies, adipo nectin, dia-
betes mellitus type II
Kratak sadr`aj: Zna~aj povezanosti antifosfolipidnih anti -
te la (aPL Abs) sa odlikama dijabetesa tip II jo{ nije razja{ njen.
Cilj rada bilo je ispitivanje povezanosti aPL Abs sa adi -
 ponektinom i neesterifikovanim masnim kiselinama (NEFA)
kod pacijenata sa dijabetesom tip II bez mikro i/ili makro -
vaskularnih komplikacija i analiziranje razlika u navedenim
parametrima izme|u mu{karaca i `ena sa dijabetesom. Kod
mu{karaca sa dijabetesom tip II pokazana je po zitivna ko -
relacija izme|u koncentracija NEFA i anti-oxLDL antitela
(r=0,334, p=0,019). Slaba ali statisti~ki zna~ajna korelacija
izme|u koncentracija adiponektina i IgM izotipa anti-aneksin
A5 antitela prona|ena je kod pacijenata sa dijabetesom tip II
(r=0,285, p=0,011). Pozitivna korelacija izme|u NEFA i
anti-oxLDL antitela mogla bi da bude korisna u detekciji pa -
cijenata sa prevremenom aterosklerozom u dijabetesu tip II
bez mikro i/ili makrovaskularnih komplikacija. 
Klju~ne re~i: antifosfolipidna anti te la, adi po nektin, dia-
betes mellitus tip II
Introduction
The existence of a procoagulant state has been
found in type II diabetes mellitus patients (1). Anti -
phospholipid antibodies (aPL) may cause and/or pro-
mote thrombosis (2–5). Previously it was reported
that antiphospholipid monoclonal antibodies reduced
the anticoagulant effect of annexin A5, and those
antibodies were involved in the stimulation of throm-
bin ge neration (6). Various mechanisms that explain
the roles of antiphospholipid antibodies in the patho-
genesis of the antiphospholipid syndrome have been
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proposed, but the importance of the association of
aPL Abs with the features of type II diabetes mellitus
has not yet been elucidated. 
Adiponectin is a protein secreted by adipocytes
that exerts antiinflammatory and antiatherogenic char -
 acteristics. Moreover, adiponectin has a role in the
relationship between obesity and insulin resistance
(7). Previous reports have suggested that inflamma-
tion might be considered as the link between insulin
resistance, obesity and diabetes mellitus (8).
Impaired non-esterified fatty acids (NEFA) meta -
bolism in adipose tissue is associated with some of
the features of the metabolic syndrome (9, 10). Dys -
re gulation of NEFA metabolism is atherogenic (11).
Recently it has been suggested that an associa-
tion between aPL Abs and TNF-alpha might be a pre-
dictor of a severe atherogenic profile in type II dia-
betes mellitus patients without vascular complications
(12). In the present study we investigated the associ-
ation of aPL Abs with adiponectin and NEFA in a well-
formed group of type II diabetes mellitus patients
without micro and/or macrovascular complications.
Further more, we analyzed the differences between
male and female patients with regard to the above-
mentioned para me ters. 
Patients and Methods
Patients
The study was approved by the local Ethical
Com mittee and all participants gave their written
informed consent. Well formed group of 78 consecu-
tive pa tients with type II diabetes mellitus without
micro and/or macro vascular complications was stu -
died. Pa tients were assessed for the presence of dia-
betic complications, i.e. retinopathy, nephropathy,
history of myocardial infarction and the presence of
angina pectoris. The body mass index was calculated
as the weight (kg)/height (m2). Cut-off values for
waist circumference (WC) and the waist-hip ratio
(WHR) were set as recommended (13, 14). 
Methods
Apolipoproteins AI, AII, B, E were measured by
immunonephelometry using a Behring Nephelometer
Analyzer II, Marburg, Germany. Cholesterol, triglyc-
erides, HDL-cholesterol and HbA1c were measured on
an AU2700® Chemistry analyzer (Beckman Coulter,
Clinical Diagnostics). Cut-off values for all the above-
mentioned parameters were set in accordance with the
manufacturer’s recommendations. Measure ment of the
concentrations of oxLDL (Mercodia, Sweden) was done
by ELISA. Concentrations of analyzed antibo dies were
measured by ELISA using the commercial rea gents of
Imtec Immunodiagnostika, Germany, for the detection
of anti-oxLDL (aoxLDL) antibodies, and Org entec
Diagnostika GmbH, Ger many, for the detection of anti-
cardiolipin (aCL), anti-b2gly coprotein I (ab2gpI) and
anti-annexin A5 (anxA5) antibodies. Cut-off values for
all the analyzed antibodies were set as the manufactur-
er recommended. 
Statistical analysis
Kolmogorov-Smirnov test was used to determi -
ne whether the analyzed variables followed a normal
distribution. Continuous variables were expressed as
median (25th–75th percentiles). The association
between the presence of antiphospholipid antibodies
(aCL, ab2gpI, anxA5, aoxLDL) and the anthropomor-
phic features of patients was examined by c2-test,
Mann-Whitney or t-test, when appropriate. The corre-
lation between two quantitative variables was deter-
mined with the correlation tests (Spearman’s, Pear -
son’s, when appropriate). Analyses were conducted in
SPSS 10 (SPSS, Inc, Chicago, IL, USA).
Results
Differences in the investigated parameters bet -
ween the female and male patients with type II dia-
betes mellitus are shown in Tables I and II. Waist-hip
ratio, NEFA, glucose concentrations and HbA1c were
significantly different between the female and male
type II diabetes mellitus patients. Concentrations of
the analyzed aPL Abs did not reach statistically signi -
ficant difference between the investigated female and
male subjects. 
Adiponectin concentrations were in a positive cor-
relation with HDL (r=0.423, p=0.000) and apo AI
concentrations (r=0.333, p=0.004) and in an inverse
correlation with triglyceride concentrations (r=–0.234,
p=0.039) and with WHR (r=–0.324, p=0.004). No
significant association between adi po nectin and aCL,
ab2gpI and aoxLDL Abs was found. A weak, but statis-
tically significant correlation between adiponectin con-
centrations and the IgM isotype of anti-annexin A5 anti -
bodies was found in type II diabetes mellitus pat ients
(r=0.285, p=0.011). However, logistic regression ana -
lysis failed to confirm the strength of this association. 
Concentrations of NEFA and adiponectin were
in a negative correlation (r=–0.235, p=0.047). A
positive correlation was found for NEFA concentra-
tions and BMI (r=0.244, p=0.039), HbA1C
(r=0.248, p=0.037), glucose (r=0.281, p=0.017),
apo E (r=0.327, p=0.006) and triglyceride concen-
trations (r=0.237, p=0.045). No significant associa-
tion between NEFA and the analyzed aPL Abs was
found. 
In the male patients with type II diabetes mellitus
NEFA concentrations showed positive correlations with
apoAI (r=0.361, p=0.013) and anti-oxLDL antibodies
(r=0.334, p=0.019).
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Parameters
Median (25th–75th) Female Male P value
Number 25 53
Age (years) 57 (50–62.50) 54 (47–59) n.s.
WC (cm) 99 (96.5–121.0) 108 (99–115) n.s.
WHR 0.91 (0.89–0.92) 0.93 (0.90–0.97) 0.005
Glucose (mmol/L) 6.55 (6.02–8.75) 8.20 (7.05–9.45) 0.011
HbA1c (%) 6.50 (6.10–7.17) 7.10 ( 6.70–7.90) 0.005
Cholesterol (mmol/L) 5.52 (4.49–6.63) 5.63 (4.72–6.59) n.s.
LDL (mmol/L) 3.02 (2.72–3.99) 3.39 (2.69–4.45) n.s.
HDL (mmol/L) 1.12 (0.95–1.29) 0.97 (0.83–1.19) n.s.
Triglycerides (mmol/L) 2.19 (1.44–3.58) 2.17 (1.45–3.50) n.s.
Apolipoprotein AI (g/L) 1.94 (1.69–2.29) 1.73 (1.47–1.97) n.s.
Apolipoprotein AII (mg/L) 349 (339–378) 321 (279–373) n.s.
Apolipoprotein B (g/L) 1.13 (0.97–1.41) 1.21 (1.05–1.57) n.s.
Apolipoprotein E (mg/L) 50.85 (40.42–59.77) 45.30 (34.55–57.90) n.s.
oxLDL (mU/L) 8.83 (7.98–11.65) 10.09 (8.45–11.51) n.s.
Adiponectin (μg/mL) 56.88 (36.76–83.54)   59.19 (27.51–79.49) n.s.
NEFA (mmol/L) 0.60 (0.42–0.92) 0.48 (0.36–0.66) 0.039
Table I Differences in analyzed parameters (adiponectin, NEFA, apolipoproteins) between female and male patients with type
II diabetes mellitus.
n.s. not significant
Table II Differences in analyzed antibodies between female and male patients with type II diabetes mellitus.
aanxA5, anti-annexin A5 antibodies; ab2gpI, anti-b2gpI antibodies; aCL, anticardiolipin antibodies; aoxLDL, anti-oxLDL anti -
bodies; n.s. not significant
Analyzed antibodies 
Median (25th–75th)
Female Male P value  
Number 25 53   
aCL IgG (U/mL) 5.78 (4.07–8.06) 5.64 (3.34–7.76) n.s.
aCL IgM (U/mL) 4.97 (4.03–6.19) 4.34 (2.96–6.02) n.s.
ab2gpI IgG (U/mL) 2.74 (1.12–4.80) 3.16 (0.00–5.57) n.s.
ab2gpI IgM (U/mL) 2.46 (1.49–3.43) 2.28 (1.18–3.35) n.s.
aanxA5 IgG (U/mL) 2.05 (1.05–2.57) 2.12 (1.46–2.68) n.s.
aanxA5 IgM (U/mL) 1.38 (0.99–2.16) 1.98 (1.14–2.51) n.s.
aoxLDL (IgG + IgM) (U/mL) 15.30 (12.85–20.95) 18.57 (16.49–23.75) n.s.
In the female patients with type II diabetes mel-
litus a negative correlation between adipo nectin con-
centrations and HbA1c (r=–0.481, p=0.017) was
found. Also, NEFA and HDL concentrations were in
an inverse correlation (r=–0.442, p=0.035) in the
investigated female subjects. Menopause was present
in 21 out of 25 (84%) female patients with type II dia-
betes mellitus. Two out of 25 (8%) female patients
were on hormone substitution therapy. Statistically
non-signi ficantly elevated NEFA levels were present in
five out of 19 (26.31%) menopause patients (c2=
0.003, p=0.957). In patients receiving hormone sub-
stitution therapy a significant association with ele -
vated levels of apoAI was observed (c2=6.545,
p=0.011). Also, these patients showed a significant
association with the presence of the IgG isotype of
aCL antibodies (c2=5.210, p=0.022).
Discussion
Plasma adiponectin exists in three isoforms, and
high molecular weight adiponectin (HMWA) levels
were higher in women (in comparison to the age and
BMI-matched men) because testosterone regulates
the secretion of HMWA from adipocytes, whereas
middle and low molecular weight adiponectin levels
are comparable between both genders (15).
Differences between men and women are tho ught
to be a direct effect of androgens on adiponectin syn-
thesis (16). Testosterone inhibits adiponectin secretion
from adipocytes (17), and testosterone replacement
therapy caused a decrease in adiponectin levels in hypo -
gonadal patients (15). Androgens decrease adipo nectin
levels, and androgen-induced hypoadiponectinemia
may be related to the high risk of insulin resistance and
atherosclerosis in men (17). The difference in adipo -
nectin concentrations between men and women van-
ished in patients older than 80 years, obese persons and
in patients with type II diabetes mellitus. Serum adipo -
nectin concentrations did not differ between patients
with and without type II diabetes mellitus (18). It was
reported that postmenopausal women had significantly
higher levels of adiponectin than premenopausal
women (19). However, in our study almost all of the
analyzed menopausal patients (85.71%) had elevated
adiponectin levels, and this is the explanation for the dis-
crepancy in the results. 
Adiponectin levels are lower in those with obesi-
ty (20) and type II diabetes mellitus, and the levels in -
crease with weight reduction (21). Adiponectin levels
were in a negative correlation with BMI (22–24), WC
(25), WHR (26).
No significant difference in age, WHR and adi -
ponectin levels between the female and male type II
diabetes patients was found. 
Adiponectin is negatively correlated with the
features of metabolic syndrome and other associated
features of insulin resistance and conventional cardio-
vascular risk factors. These include serum insulin,
total cholesterol, LDL, apoB100, triglycerides, glu-
cose, HbA1c, lower HDL and smaller LDL particle
size (27–29). Our findings are in concordance with
the abovementioned results in regard to the negative
correlation between adiponectin and WHR, triglyc-
eride concentrations and HbA1c (only in the female
subgroup of patients). 
Increased NEFA has an important role in the
development of insulin resistance and type II diabetes
mellitus (30, 31). Diabetes mellitus is associated with
an increased risk of CVD, and NEFA might be direct-
ly related to coronary events (32–34). Impaired NEFA
meta bolism in adipose tissue is linked to some com-
ponents of the metabolic syndrome (impaired glucose
disposal, hypertriglyceridemia, low HDL, small LDL
(9, 10). In our study, NEFA concentrations were in a
negative correlation with adiponectin levels, and in
a positive correlation with glucose, triglycerides,
HbA1c, apoE. 
It was reported that oxidized LDL are the product
of oxidation of their polyunsaturated fatty acid compo-
nent, and that the uptake of oxLDL by macrophages
activates the immune system. Increased immunogenic-
ity of the oxLDL molecule elicits the formation of anti-
oxLDL antibodies. The presence of anti-oxLDL anti-
bodies is associated with atherosclerosis (35). In our
study, in the male patients with type II diabetes mellitus
a positive correlation between the NEFA concentrations
and anti-oxLDL antibodies titers was shown.
It was suggested that adiponectin should serve as
a marker for the progression of atherosclerosis (36)
and may be helpful in preventing the development of
atherosclerotic vascular disease or its complications
(37). Based on our results, the presence of a positive
correlation between NEFA and anti-oxLDL antibodies
might be useful in the detection of patients with pre-
mature atherosclerosis among type II diabetes melli-
tus patients without any micro and/or macrovascular
complications.
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